Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus IMATINIB MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus IMATINIB MESYLATE.
CAPRELSA vs IMATINIB MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
Imatinib mesylate is a tyrosine kinase inhibitor that selectively inhibits BCR-ABL, c-KIT, and PDGFR tyrosine kinases, thereby blocking signal transduction pathways involved in cellular proliferation and survival.
300 mg orally once daily, with or without food.
400 mg orally once daily, with a meal and a large glass of water. Dose escalation to 600 mg or 800 mg daily may be considered in cases of disease progression.
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
Terminal elimination half-life is approximately 18 hours (range 13–22 hours) for the parent drug; the active metabolite N-desmethyl imatinib has a half-life of about 40 hours. Clinically, this supports once-daily dosing.
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Primarily fecal (68% of dose) as metabolites; renal excretion accounts for approximately 13% of dose (5% as unchanged drug and 8% as metabolites).
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor